Trial Profile
A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms PARADIGM
- Sponsors Takeda
- 06 Jun 2023 Results (n=802) a biomarker study of the phase III PARADIGM trial assessing presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 18 Apr 2023 Results published in the JAMA: the Journal of the American Medical Association
- 13 Sep 2022 Results asseesing Early tumor shrinkage (ETS) and depth of response (DpR) and their correlation with OS and PFS , presented at the 47th European Society for Medical Oncology Congress